Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...

Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...

We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

Kling Biotherapeutics (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announces the appointments of Alessandra Micaela Villa as ...

Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on MRUS stock, giving a Buy rating yesterday.Pick the best stocks ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Rare NRG1 Fusion Therapeutics ...

Netherlands-based clinical-stage biotech Merus on Saturday announced interim clinical data as of a July 5, 2024 data cutoff ...

FDA approves zenocutuzumab for advanced non-small-cell lung cancer and pancreatic cancer with NRG1 fusion, offering new hope ...

Deal-making featured strongly among last week’s news, first with PCT Therapeutics inking an up to 2.9 billion collaboration ...

The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut ...